NRBO - NeuroBo Market Capitalization-to-Revenue Ratio
Risks for NeuroBo Pharmaceuticals (NRBO) are linked to the costly thermal logistics of biomaterials, which complicate supply chains. The price-to-sales multiple serves as a stability indicator, where the level of is the current value. Positive sentiment is driven by the bet on the commercialization of obesity and MASH treatments, as well as anticipation of mid-stage clinical trial results supported by industry behemoths.
Metric breakdowns and analytics for NeuroBo Pharmaceuticals (NRBO)
- current quotes and average value forecast:
- market capitalization statistics:
- book capitalization indicators:
- issuer credit burden and liquidity indicators:
Total Debt to Capital NeuroBo Pharmaceuticals|NRBO - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital neurobopharma.com|NRBO - Company Debts|Debt to Book Value NeuroBo Pharma|NRBO - Company Long-Term Debts|Company Short-Term Debts NeuroBo Pharmaceuticals|Quick Liquidity Indicator neurobopharma.com
- earnings and valuation multiples indicators:
NRBO - Net Profit|Expected Net Profit NeuroBo Pharmaceuticals|NRBO - Price to Earnings Ratio|Forward P/E Multiple NeuroBo Pharmaceuticals|NRBO - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio NeuroBo Pharma|NRBO - Operating profit EBITDA|Net earnings per share for the last four quarters NeuroBo Pharmaceuticals|NRBO - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months neurobopharma.com|NRBO - Earnings growth in current year|Earnings growth forecast for next year NeuroBo Pharmaceuticals
- issuer revenue and sales details:
Fundamental company analysis:NRBO (NeuroBo Pharmaceuticals, Inc.)
For NeuroBo Pharmaceuticals (NRBO), a developer of anti-obesity drugs, this ratio determines the company's market value relative to its current sales. By analyzing the business valuation via P/S, an investor compares market capitalization with revenue volume, which allows for an assessment of whether the stock price is justified in anticipation of mass insurance payouts for new medications and helps identify a potential discount or risks of asset undervaluation.
Competing companies
BIIB (Biogen) - Market Capitalization-to-Revenue Ratio|P/S Multiple NBIX (Neurocrine Corp)|Regencell Bioscience - Price-to-Revenue Ratio|Axsome Therapeutics - P/S Multiple|Market Capitalization-to-Revenue Ratio ACAD (ACADIA Pharmaceuticals)|Xenon (XENE) - Price-to-Revenue Ratio|Price to Sales Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - P/S Multiple|CPRX: Market Capitalization-to-Revenue Ratio|P/S Multiple DNLI|Price-to-Revenue Coefficient Harmony Biosciences|Biohaven Ltd - Market Cap to Revenue|P/S Multiple Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Market Cap to Revenue|Price-to-Revenue Coefficient Praxis Corp PRAX|AVXL: P/S Multiple|CBLL (ceribell.com) - Price-to-Revenue Ratio|PRTA (Prothena Corporation) - P/S Multiple|Market Cap to Revenue alector.com (ALEC)|Price-to-Revenue Ratio Annexon, Inc. (ANNX)|OMER - Price to Sales|P/S Multiple NGNE (Neurogene Inc)|AC Immune (ACIU) - Price to Sales|Voyager Therapeutics Inc - P/S Multiple|Neumora (NMRA) - Market Cap to Revenue|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|Market Cap to Revenue cogrx.com (CGTX)|Price-to-Revenue Ratio Inhibikase Therapeutics Inc (IKT)|Price-to-Revenue Coefficient Cassava Sciences|P/S Multiple ASRT (Assertio Holdings)|COYA - Market Cap to Revenue|vistagen.com - P/S Multiple|OVID: Price-to-Revenue Ratio|Acumen Pharmaceuticals, Inc (ABOS) - Price-to-Revenue Ratio|CervoMed Inc - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Alterity Therapeutics Limited|clene.com (CLNN) - Price-to-Revenue Coefficient|Market Cap to Revenue PEPG (PepGen Inc)|P/S Multiple jupiterneurosciences.com (JUNS)|Price-to-Revenue Ratio Relmada Therapeutics, Inc. RLMD|ANVS: Market Cap to Revenue Ratio|Grace Tx - P/S Multiple|AIFF (Firefly Neuroscience Inc) - Market Cap to Revenue Ratio|KLTO: P/S Multiple|NeuroSense Therapeutics, Ltd. (NRSN) - P/S Multiple|Price-to-Revenue Ratio Reviva Pharmaceuticals, Inc.|Market Cap to Revenue metaviatx.com (MTVA)|P/S Multiple NRXS|HSDT - Price to Sales|Passage Bio, Inc. - Market Cap to Revenue|bionomics.com.au (NEUP) - Price to Sales|Minerva - P/S Multiple|Market Capitalization-to-Revenue Ratio ATHA (Athira Pharma Inc)|ADXN: P/S Multiple|Market Cap to Revenue Ratio ALZN|CYCN (Cyclerion Therapeutics Inc.) - P/S Multiple|PTIX (Protagenic Therapeutics) - Market Cap to Sales Volume|P/S Multiple KTTA|Price-to-Revenue Coefficient Cortigent|P/S Multiple ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Price-to-Revenue Ratio|Cara Therapeutics Inc. - P/S Multiple|Chromocell Therapeutics (CHRO) - Market Cap to Revenue|ELYM: P/S Multiple|Market Cap to Revenue Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - P/S Multiple|Marinus - Price-to-Sales Ratio|P/S Multiple NKGN|SAGE: Price-to-Sales Ratio|Synaptogenix Inc. - Market Cap to Revenue|Market Cap to Sales Volume TRVN (Trevena Inc.)|Vigil Neuroscience, Inc. - P/S Multiple|Anew Medical (WENA) - Market Cap to Revenue|CERE (Cerevel Corp) - Market Cap to Revenue
